Financial/nonfinancial disclosures: The authors have reported to CHEST the following conflicts: Prof Heaney has received grant funding from Medimmune LLC, Novartis UK (an affiliate of Novartis AG), Genentech Inc, and GlaxoSmithKline plc; has taken part in advisory boards and given lectures at meetings supported by GlaxoSmithKline plc, Merck Sharpe & Dohme Corp, Nycomed A/S, Novartis AG, and AstraZeneca plc; has received support funding to attend international respiratory meetings (AstraZeneca plc, Chiesi Ltd, Novartis AG, and GlaxoSmithKline plc); and has taken part in asthma clinical trials (GlaxoSmithKline plc and Genentech Inc) for which his institution was remunerated. Dr Niven received an unrestricted grant of £10,000 from Novartis in 2010 toward development of clinical services at the University Hospital of South Manchester; has lectured in the field of severe allergic asthma at Novartis AG-sponsored meetings receiving honoraria in total not exceeding £5,000 in the last 3 years; has lectured at pharmaceutically sponsored meetings for the following pharmaceutical companies in the last 3 years: Astra Zeneca (< £1,000), GlaxoSmithKline (< £5,000) and Chiesi Ltd (<£1,000); sat on advisory boards for the following companies in the last 3 years (Vectura, Novartis AG, GlaxoSmithKline), receiving reimbursement not exceeding £1,000; and received sponsorship support to attend international academic meetings. Dr Bucknall has been funded to attend American Thoracic Society meetings by Boehringer Ingelheim GmbH, and has been funded by AstraZeneca plc, GlaxoSmithKline plc, and Novartis AG to speak at local and national meetings. Dr Rowe is now a full-time employee of Janssen-Cilag Ltd where he works in the Research and Development IT Department supporting external researchers in using the TranSMART infomatics platform. Dr Bhavsar has received grant money from GlaxoSmithKline plc. Prof Chung has received university grant monies from the Wellcome Trust, UK Medical Research Council, Asthma UK, the US National Institutes of Health, and the UK National Environmental Research Council; and has been remunerated by GlaxoSmithKline plc and Gilead Sciences Inc for participating at advisory board meetings, and by Novartis AG and GlaxoSmithKline plc for participating in speaking activities. Dr Menzies-Gow has participated on advisory boards for Novartis AG, Genentech, GlaxoSmithKline plc, and Napp Pharmaceuticals Ltd; has received travel and accommodation to attend international conferences from GlaxoSmithKline plc, Novartis AG, and Boehringer Ingelheim GmbH; has received lecture fees from GlaxoSmithKline plc, Novartis AG, and Chiesi Ltd; and has received payments to his institution for participation in clinical trials with GlaxoSmithKline plc and Novartis AG. The remaining authors have reported that no potential conflicts of interest exist with any companies/organizations whose products or services may be discussed in this article.